Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 clinical trial for its steroid receptor coactivator 3 knock-out Regulatory T (Treg) cells (SRC3-KO) in patients with solid-tumor

Next Previous
Trial Profile

Phase 1/2 clinical trial for its steroid receptor coactivator 3 knock-out Regulatory T (Treg) cells (SRC3-KO) in patients with solid-tumor

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 16 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SRC-3-KO-Treg-cell-therapy-CoRegen (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 16 Jul 2025 New trial record
  • 09 Jul 2025 According to CoRegen media release, the company announce close of a $93,390,000 million financing. The proceed from this round will support Phase 1/2 trial of steroid receptor coactivator 3 knock-out Regulatory T (Treg) cells (SRC3-KO),which is expected to began in first half of 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top